Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment

Starting soon

Conditions studied: Prophylactic Anticoagulation

In brief

Intensive care patients have an increased risk of venous thromboembolic events (deep vein thrombosis (DVT) and pulmonary embolism (PE)) due to the presence of general risk factors for thrombosis (age, immobilization, obesity, prothrombotic history, etc.), but also risk factors specifically related to their stay in intensive care (sepsis, vasopressors, organ failure, mechanical ventilation, sedation, renal failure, central venous catheters). In addition, these same patients also have an increased risk of hemorrhagic events, mainly associated with coagulation disorders and thrombocytopenia. Given this increased risk of thrombosis, it is recommended that heparin thromboprophylaxis be used in intensive care patients in the absence of contraindications. In current practice, when faced with a patient with impaired renal function, there is significant heterogeneity in the prescription of thromboprophylaxis between centers and intensive care physicians: some will use enoxaparin, dalteparin, or tinzaparin regardless of renal function, while others will use subcutaneous calciparin or IVSE UFH. The PANTHER study is a prospective, multicenter, observational study that aims to evaluate the safety and efficacy of heparin thromboprophylaxis in critically ill patients with renal failure. The goal is to assess whether there is a difference in bleeding risk and thromboprophylaxis efficacy depending on the molecule used.

Key facts

Study ID

NCT07365644

Run by

Centre Hospitalier le Mans

People needed

1111

Starts

2026-01-01

Expected to finish

2028-02-01

Last updated by the study team

2026-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of impaired renal function (one of the two criteria must be met, both criteria may be met):
• Glomerular filtration rate (GFR) <30ml/min/1.7m² according to the MDRD or CKD-EPI formula.
• Acute renal failure (observed or presumed increase in creatinine in the last 7 days) KDIGO stage 3 (creatinine ≥3 times baseline creatinine or ≥354 µmol/L (4 mg/dL) or urine output <0.3 mL/kg/h for ≥24 hours or initiation of extrarenal clearance or anuria for ≥12 hours)
• Expected length of stay in intensive care ≥48 hours

You may not qualify if…

• Age ≤ 18 years
• Long-term dialysis patient
• Current or recent hemorrhage during this hospitalization
• Patient receiving curative anticoagulation or treated long-term prior to admission with curative anticoagulation.
• Thrombosis present on admission

Where it is running

• CHU Angers — Angers, France
• CHU bordeaux — Bordeaux, France
• CHU Brest — Brest, France
• CHU Caen — Caen, France
• Centre Hospitalier Le Mans — Le Mans, France
• Groupe Hospitalier Bretagne Sud — Lorient, France
• CHR Metz-Thionville site Mercy — Metz, France
• CHRU Nancy — Nancy, France
• CHU Nantes — Nantes, France
• CHU Orléans — Orléans, France
• CHU Poitiers — Poitiers, France
• CHU Rennes — Rennes, France
• Centre Hospitalier de Saint-Nazaire — Saint-Nazaire, France
• CHR Metz-Thionville Hôpital Bel-Air — Thionville, France
• CHU Tours — Tours, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.